Sensitivity of AML cells to Ara-C and PIK-75
| AML . | Ara-C IC50 (nM) . | PIK-75 IC50 (nM) . |
|---|---|---|
| AML cell population | ||
| Bulk AML | 8400 (n = 20) | 414 (n = 44) |
| CD34+CD38-CD123+ | 156 000 (n = 20) | 431 (n = 44) |
| AML patient sample | ||
| De novo AML | Nd | 284 (n = 7) |
| Relapsed AML | Nd | 346 (n = 7) |
| Cytogenetic risk group | ||
| Favorable* | 3000 (n = 5) | 444 (n = 6) |
| Intermediate† | 4350 (n = 10) | 367 (n = 28) |
| Adverse‡ | 30 500 (n = 5) | 726 (n = 9) |
| FLT3-ITD and NPM status | ||
| FLT3-ITD+ | 111 000 (n = 6) | 360 (n =1 7) |
| FLT3-ITD− | 4800 (n = 14) | 428 (n = 27) |
| NPM+ | 5950 (n = 6) | 367 (n = 16) |
| NPM− | 10 400 (n = 14) | 444 ( n= 8) |
| AML . | Ara-C IC50 (nM) . | PIK-75 IC50 (nM) . |
|---|---|---|
| AML cell population | ||
| Bulk AML | 8400 (n = 20) | 414 (n = 44) |
| CD34+CD38-CD123+ | 156 000 (n = 20) | 431 (n = 44) |
| AML patient sample | ||
| De novo AML | Nd | 284 (n = 7) |
| Relapsed AML | Nd | 346 (n = 7) |
| Cytogenetic risk group | ||
| Favorable* | 3000 (n = 5) | 444 (n = 6) |
| Intermediate† | 4350 (n = 10) | 367 (n = 28) |
| Adverse‡ | 30 500 (n = 5) | 726 (n = 9) |
| FLT3-ITD and NPM status | ||
| FLT3-ITD+ | 111 000 (n = 6) | 360 (n =1 7) |
| FLT3-ITD− | 4800 (n = 14) | 428 (n = 27) |
| NPM+ | 5950 (n = 6) | 367 (n = 16) |
| NPM− | 10 400 (n = 14) | 444 ( n= 8) |
Nd, not determined.
Favorable is defined as t(8;21)(q22;q22) or inv(16)(p13.1q22) or t(16;16)(p13.1;q22).
Intermediate is defined as normal karyotype or t(9;11)(p22;q23) or cytogenetic abnormalities not classified as favorable or adverse.
Adverse is defined as inv(3)(q21q26.2) or t(3;3)(q21;q26.2) or t(6;9)(p23;q34) or t(v;11)(v;q23) or −5 or del(5q) or −7 or abnl(17p) or complex karyotype.